Charles Moore,  —

A proverbial elephant crowding the drug-accessibility room is getting harder and harder to ignore. The high cost of some new pharmaceutical medicines designed to treat devastating and often deadly, but relatively rare disease conditions, combined with concerns over the sustainability of government-led public health systems and current…

A team of research scientists at the University of Freiburg (Albert-Ludwigs-Universität Freiburg) at Freiburg im Breisgau, Baden-Württemberg, Germany, the University of Geneva, and the University of Grenoble report that they have succeeded in preventing the hospital-acquired bacteria Pseudomonas aeruginosa, a pathogen particularly dangerous to persons with Cystic Fibrosis (CF), from…

Vertex Pharmaceuticals Incorporated has been grabbing headlines recently related to its revolutionary cystic fibrosis drug Kalydeco (ivacaftor), which is currently approved for people with CF aged 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Cambridge, Massachusetts-based Vertex Pharmaceuticals Incorporated announced Monday that it has signed a letter of intent with the pan-Canadian Pricing Alliance (pCPA) to enable public reimbursement of Kalydeco (ivacaftor) drug therapy for treatment of eligible Canadians ages 6 and older with cystic fibrosis (CF) who have the G551D gene…

A recent study published in the Iranian Journal of Pediatrics suggests that taking probiotics supplements can help improve quality of life for patients with cystic fibrosis (CF). Persons with CF (and many other disease conditions) frequently suffer from imbalanced intestinal microbiota ecosystems and suffer consequent dysregulated immune functionalities exacerbated…

In some ways, it’s both the best of times and the worst of times for persons afflicted with certain serious disease conditions, such as cystic fibrosis. On the one hand, there have been encouraging and potentially life-changing breakthroughs in terms of therapy options. On the other, these new drugs can…

Canada’s CTV News reported late last week that the province of Alberta’s health minister has successfully negotiated a tentative deal that will allow Canadian provinces to cover the cost to their provincial pharmacare plans of the multiple sclerosis (MS) drug Kalydeco, used for treatment of cystic fibrosis (CF)…

Austin-based International Biophysics Corporation’s marquee product, AffloVest, is a cutting-edge technology airway clearance vest that represents a major advance in treatment of respiratory diseases such as Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, and similar related ailments. This High Frequency Chest Wall Oscillation (HFCWO) vest that gives…

A new study by researchers at the University of California, San Diego School of Medicine finds that technology helps adolescents with chronic diseases (ACD) in developing the independent, self-management skills they need as they assume the responsibilities and privileges of adulthood. Teens with chronic diseases such as cystic fibrosis,…

Montreal-based biotech startup Laurent Pharmaceuticals Inc. announced Wednesday that the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal has begun enrolling patients in an investigator-initiated clinical trial evaluating the safety, tolerability and pharmacokinetics of a novel oral formulation of Fenretinide in adult subjects with Cystic…